OnCo
peoplePerson

Dong-Wan Kim

Dong-Wan Kim is a thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.

Dong-Wan Kim has been an investigator on the PROFILE, ALTA, and later ALK/ROS1 trials and on EGFR studies, helping establish targeted therapy for fusion-driven lung cancer.

Role
Professor of Internal Medicine; thoracic oncology
Specialisms
Lung cancerALK and ROS1 fusionsTargeted therapy

Papers

1top
TitleJournalYear
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L)NEJM2018

Key papers

1top
rctNew England Journal of Medicine 2020changed practice
CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer

For ALK-positive advanced lung cancer, lorlatinib as the first drug offers the possibility of many years without progression and strong protection against brain metastases. Alectinib and brigatinib remain alternatives with a gentler side-effect profile; the choice weighs lorlatinib's cognitive, metabolic and weight effects against its unmatched duration of control.

Connected

7top

cancers

1
Non-small-cell lung cancer

targets

2
ALKROS1

drugs

2
ApprovedSmall-molecule kinase inhibitor (ALK/ROS1)
Lorlatinib · Lorbrena
ApprovedSmall-molecule kinase inhibitor (ROS1 / NTRK)
Repotrectinib · Augtyro

institutions

1
Seoul National University Hospital

key papers

1
CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer